Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Enovis from “hold” to “buy.” Overall analyst sentiment is “Moderate Buy,” with 10 Buy, one Hold, and one Sell rating, plus a consensus price target of $37.25.
• Enovis shares were trading at $19.92 after falling 12.7%, near the lower end of their 52-week range. The company’s latest quarterly results exceeded expectations, reporting $0.90 in EPS versus an $0.85 consensus estimate and $582.78 million in revenue.
• Company insiders bought 23,293 shares worth approximately $449,599 during the last quarter, while institutional investors—including Paradigm Capital and Bank of America—also established or expanded positions.

Enovis (NYSE:ENOV - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

ENOV has been the topic of a number of other research reports. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Canaccord Genuity Group reduced their price objective on shares of Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, August 17th. UBS Group reissued a "buy" rating and set a $44.00 target price on shares of Enovis in a research report on Monday, October 5th. Zacks Research raised shares of Enovis from a "strong sell" rating to a "hold" rating in a research report on Wednesday, July 29th. Finally, Citigroup restated a "market outperform" rating on shares of Enovis in a research note on Wednesday, September 2nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.25.

Enovis Trading Down 12.7%

Shares of NYSE ENOV opened at $19.92 on Friday. Enovis has a 1-year low of $16.70 and a 1-year high of $32.41. The business has a fifty day moving average price of $20.02 and a 200 day moving average price of $23.08. The stock has a market capitalization of $1.15 billion, a P/E ratio of -1.03 and a beta of 1.37. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm's quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis will post 3.15 EPS for the current fiscal year.

Insider Transactions at Enovis

In other Enovis news, CEO Damien Mcdonald purchased 13,035 shares of the stock in a transaction on Friday, September 4th. The stock was acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. The trade was a 5.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Oliver Engert purchased 2,660 shares of the stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $18.80 per share, with a total value of $50,008.00. Following the acquisition, the insider owned 63,898 shares of the company's stock, valued at approximately $1,201,282.40. This represents a 4.34% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 23,293 shares of company stock valued at $449,599. 2.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enovis

A number of large investors have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY purchased a new position in Enovis during the 2nd quarter worth approximately $28,533,000. Bank of America Corp DE purchased a new stake in shares of Enovis in the 2nd quarter valued at $11,502,000. Man Group plc purchased a new stake in shares of Enovis in the 2nd quarter valued at $8,711,000. Front Street Capital Management Inc. boosted its holdings in shares of Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company's stock valued at $16,973,000 after acquiring an additional 384,124 shares during the last quarter. Finally, Private Management Group Inc. increased its stake in shares of Enovis by 38.8% in the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company's stock worth $28,257,000 after acquiring an additional 381,705 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis Corporation NYSE: ENOV is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company's products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.